The Good Veterinary Workplaces Voluntary Code sets out various criteria for what makes a good workplace, based on a new evidence-based BVA policy position.
The code is accompanied by a workbook which veterinary teams can work through together and consider how they might meet a range of criteria. They can also download, sign and display a Voluntary Code poster signalling their commitment to working towards being a good veterinary workplace.
Teams will be asked to assess what they already do well in areas including health and wellbeing, diversity and equality, workload and flexibility, and providing opportunities for personal and career development, as well as identifying areas for improvement and any HR and management processes that need to be put in place to achieve a positive workplace culture.
At the same time, the BVA has also launched its Good Veterinary Workplaces policy position, a paper which offers 64 recommendations for employers and staff on how to offer a fair and rewarding work environment where everyone feels valued.
The BVA says it decided to develop the Good Veterinary Workplaces policy off the back of an extensive body of work looking at workforce issues in the profession, including recruitment and retention challenges, a lack of diversity across the workforce, and general high levels of stress and burn-out in veterinary teams.
The joint BVA/RCVS-led Vet Futures project identified the need to explore the work-related challenges facing vets and take action to create a sustainable and thriving workforce that can maximise its potential.
Gudrun Ravetz, Chair of the Good Workplace Working Group, said: “I’m absolutely delighted to see the launch of our valuable and comprehensive policy, which sets out a vision of the good veterinary workplaces that we should all be striving to create across the profession. This vision has been shaped by valuable contributions from across the veterinary community, and it’s also been really useful to draw on good practice in the wider world of work.
“Each and every one of us deserves to work in a setting where we feel valued, supported and fairly rewarded for the contribution we make, but sadly this isn’t the reality for all veterinary professionals. By setting out the steps that all veterinary workplaces can take to offer a more welcoming and inclusive environment, with measures in place to help them address issues and continue to improve, we hope to see more workplaces where staff can thrive and enjoy a fulfilling career.”
Daniella Dos Santos, BVA Senior Vice President, said: “It’s time for us all to take action to create a culture shift in veterinary workplaces. That means taking positive steps so that diversity and inclusion is championed at all levels, all team members have access to personal and professional development opportunities, and there is recognition that prioritising staff wellbeing is good for businesses.
“In creating the Voluntary Code and workbook, we’ve purposefully made this something that isn’t driven from the top down but is instead something that everyone in the team can feel empowered to feed into and sign up to. This is a golden opportunity for our profession to take ownership of our workplaces, improve conditions, and make sure that we have positive working environments in which we can all take pride.”
The award, which is sponsored by Zoetis, was given online this year at an event hosted by sports television presenter Mark Durden-Smith and Chloe Ryan, the editor of Poultry Business.
William was brought up on a sheep farm in Nottinghamshire and as a youngster bred rare breed poultry, selling eggs to local people in the village. He graduated at Nottingham University, did a poultry internship with a practice in the North West and worked there initially. Four years ago, he set up his own practice Avivets, at High Legh in Cheshire, dedicated to the poultry and game bird sector. He guest lectures at the Universities of Nottingham and Surrey and is an official veterinarian for avian exports. He sits on the RSPCA’s technical standards advisory board and was recently appointed veterinary advisor for the NFU poultry board.
Chloe Ryan said he had impressed the judges ‘with his enthusiasm for poultry veterinary knowledge and entrepreneurship. He has shown an excellent level of dedication, enriching his experience and qualifications through continuous professional development to farms and flocks as evidenced by glowing praise from a long list of clients.’
Lucy Berriman, Zoetis UK poultry national account manager, said: “Zoetis is proud to be sponsors of this new award for the industry’s poultry vets.
"It gives hardworking individuals the chance to shine and illustrate their commitment to the poultry industry. Congratulations to Will for this fabulous achievement, and well done to the other two finalists."
The other finalists were Helena Brewer, who joined the Poultry Health Services team at Sheriff Hutton, near York, after studying at the Royal (Dick) School at Edinburgh and the Royal Veterinary College, and Henry Lamb, who has worked at Crowshall Veterinary Services in Norfolk since graduating at the Royal Veterinary College.
A few examples of the products in J.A.K Marketing's 'ThinkGreen' portfolio include the Purfect Anaesorber, BAG’EMS biodegradable poop bags, Tick Twister products (made from recycled plastic) and Bamboo stick cotton buds.
The website also gives a snapshot of the sorts of things that J.A.K itself does to reduce its impact on the environment, including the use of environmentally-friendly brown paper and recycled cardboard boxes for packaging. The company has also switched to certified sustainable FSC paper for most of its printed marketing materials (including the master catalogue) and is working with courier companies who have targets in reducing CO2 emissions.
Managing Director, John Holland said: "J.A.K Marketing is committed to the protection and preservation of the world’s ecosystem. By undertaking our productivity and operations responsibly and sustainably, we recognise that reducing the environmental impact of our activities is very important. We will strive to achieve environmental excellence within the veterinary industry and will continue to work closely with our employees and commercial partners to establish and follow the principles of our ThinkGreen policy."
Sales Director, James Johnson said: "With growing interest towards the protection of the environment, we need to make it easier for veterinary practices to identify products where there is a benefit to the environment by simply switching to a like for like ‘greener’ alternative. As part of our long-term strategy, we are dedicated to growing this area of our business, welcoming feedback from the profession of how we can all work together to achieve this."
Those wanting to offer inspiration and feedback can do so on the form at the bottom of the ‘ThinkGreen’ page: www.jakmarketing.co.uk/thinkgreen.
Hill's Pet Nutrition has enhanced its portfolio of prescription diets for the management of FLUTD with the launch of Feline c/d Multicare Reduced Calorie and a 'taste upgrade' for Feline c/d Multicare.
Prescription Diet Feline c/d Multicare Reduced Calorie is a new dry product designed to manage the higher incidence of FLUTD in overweight cats (FLUTD is 49% more prevalent in overweight and obese cats2). According to Hill's, the controlled fat and calorie levels in c/d Multicare Reduced Calorie and clinically proven levels of L-carnitine help to reduce fat build up and maintain lean muscles mass. Like c/d Multicare, its formula also dissolves sterile struvite uroliths in 14 days1.
Hill's says Prescription Diet c/d Multicare Reduced Calorie is formulated with omega-3 fatty acids to reduce the distress and discomfort associated with conditions such as FIC (Feline Idiopathic Cystitis); in addition obesity has been associated with systemic inflammation3 for which omega-3 fatty acids are beneficial4,5.
Prescription Diet Feline c/d Multicare Chicken dry kibble has had its taste improved; Hill's says studies show it is now preferred over the leading competitor's brand by a wide margin6. Apparently, the improvement in flavour is partly down to the new shape of the kibble.
Lastly, Hill's is highlighting a prospective study by MacLeay et al, the preliminary results of which were reported at the American College of Veterinary Internal Medicine Forum in May 2010. In the study, cats with uroliths suspected to be struvite (based on radiographic appearance) were fed Prescription Diet Feline c/d Multicare and rapid dissolution of the stones occurred in as little as two weeks.
References
Krka says Milprazon Chewable is the first wormer in its category with proven palatability for dogs based on EMA Testing Guidelines.
In a study¹, more than 85% of dogs ate the tablet ‘voluntarily’, with 75% taking it unprompted from their food bowl.
Milprazon chewable is available in a range of presentations suitable for puppies from two weeks old (0.5kg) and kittens from six weeks old.
Milprazon comes in colour-coded packaging for easier dispensing.
Will Ridgway, Krka’s National Sales Manager said: "Milprazon Chewable is a premium product.
"It offers pet owners the reliability of Milbemycin oxime and Praziquantel, together with enhanced palatability, while supporting practice profitability."
Reference
Clare graduated from the University of Glasgow in 1991 and, following an internship at the University of Pennsylvania and general practice in Cambridgeshire, she completed a BSAVA/Petsavers Residency and was Staff Clinician in Neurology at the Royal Veterinary College.
Aged 26, she became the youngest ever Diplomate of the European College of Veterinary Neurology and three year later became a RCVS Specialist.
For 16 years, she operated a neurology and neurosurgery referral service at the Stone Lion Veterinary Hospital in Wimbledon and was awarded a PhD from Utrecht University in 2007.
Clare joined Fitzpatrick Referrals and the University of Surrey in 2013, was made a Fellow of the Royal College of Veterinary Surgeons in 2016 and awarded a Professorship of Veterinary Neurology in 2018.
Clare was made a Fellow of the Royal College of Veterinary Surgeons in 2016 in recognition of her meritorious contribution to the profession, including 25 years’ research into ‘Chiari-like malformation and syringomyelia’ in dogs.
Clare said: “I will be building and strengthening the neurology service at Wear to make it not just the leading centre in the North East, but in Europe.
“I love collaborating with others to find answers to the clinical problems we face and so, as well as potential partnership with my colleagues in the other disciplines at Wear, I hope to initiate or contribute to other multi-centre studies through the Linnaeus group.
“I am passionate about teaching and learning through collaboration, and I hope to bring multi-disciplinary rounds to the practice including neuro-radiology-neuropathology and neurology- behaviour.”
The company says that as soon as it discovered the unauthorised external access to its systems, it took them offline and started working to contain the threat.
Specialist third party consultants have been engaged to investigate the nature and extent of the incident and CVS has also informed the relevant authorities, including the Information Commissioner’s Office, because of the risk of malicious access to personal information.
The company says the majority of IT services for its practices and business functions have now been restored, but due to the increased levels of security and monitoring, some systems are not working as efficiently as before.
CVS also says that as a result of the incident, it is bringing forward plans to migrate its practice management system and related IT infrastructure to the cloud.
Analysis of the incident is ongoing and CVS says it will provide a further update in due course.
Robexera is a COX2 NSAID formulation which delivers anti-inflammatory pain relief with a once-a-day dosing regime2,3,4.
The product is presented as a flavoured chewable tablet for easier administration by pet owners.
For simplicity when dispensing, it comes in four strengths with colour coded boxes, perforated blisters and a set of PIL sheets that convert to prescribing envelopes in each pack.
Charlotte Read, Krka’s UK Key Account Manager, said: “Delivering reliable, cost-effective perioperative pain relief for soft tissue surgery is an everyday concern for veterinary practices, while OA is the most common cause of chronic pain in dogs5.
"This is why we’re particularly pleased to announce the first generic robenacoxib, Robexera.
“Bioequivalent to the originator product6, Robexera provides fast-acting and targeted pain relief, giving enhanced value to veterinary practices and enabling them to offer their clients improved affordability, particularly for those whose animals are on long term pain-management programmes or have other health issues.”
Viktor Kozjan, General Manager Krka UK, added: “The launch of Robexera is further confirmation of Krka’s commitment to develop solutions that are tried and trusted but also flexible and affordable for our customers and their clients.”
Robexera is now available to order from all national UK veterinary wholesalers.
Vetoquinol has announced the launch of Rubenal®, a new product for use in renal health management for dogs and cats.
Normal kidney function is dependent upon normal nephron and interstitial tissue structure. When the balance of renal health is tipped, this structure can change and fibrous tissue can accumulate.
Simon Boulton, Rubenal®'s product manager said: "Rubenal® is the first palatable veterinary formulation of Rheum officinale available for use in both dogs and cats. It can be used as an aid to the maintenance of the normal renal fibrotic architecture."
The company has also produced a new guide to the management of chronic renal failure in dogs and cats: Chronic Kidney Disease: Addressing quality of life and life expectancy.
Simon said: "Vetoquinol is dedicated to supporting renal health and the guide is designed to illustrate factors which can affect both quality and quantity of life, including hyperphosphataemia, hypertension, proteinuria, azotaemia and fibrosis in renal disease."
The booklet contains guidelines on the appropriate management of these factors including a wall chart reference guide.
For more information about Rubenal, or a free copy of the guide, please contact your Vetoquinol representative or telephone 0800 1698197.
Written by members of BSAVA Scientific Committee, together with specialists in internal medicine and neurology, the document explains that there are limited studies showing beneficial effects of CBD, and those that there are need to be interpreted with caution as they involved small sample sizes and used unlicensed products which may have contained other components which could have influenced the results.
The document also explains that legally, CBD products must be prescribed by a veterinary surgeons and not used instead of a medication with proven efficacy.
Caroline Kisielewicz, BSAVA Scientific Committee member and one of the authors of the document said: “Information regarding the effects of cannabinoids on animals is predominantly at the stage of pre-clinical testing of individual substances in mice, rats and guinea pigs. There are limited clinical studies looking at the effects of CBD in dogs, and no reported studies in cats.
"There are many reports describing possible beneficial effects and therapeutic potential in humans, and subsequently pet owners may ask their vet about using cannabinoids to treat veterinary patients. This document aims to provide a broad overview of the available evidence base and legal position in the UK for veterinary team members."
BSAVA President, Ian Ramsey added: "The development of this information is in direct response to an increased interest in the use of CBD to treat cats and dogs. Furthermore, the guidance supports BSAVA’s mission to promote excellence in small animal practice through community, education and science."
The BSAVA position on CBD can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443514.chap8#html_fulltext.
Elanco Companion Animal Health has launched Recuvyra 50mg/ml transdermal solution for dogs, the first transdermal fentanyl solution to be licensed for the control of postoperative pain associated with major orthopaedic and soft tissue surgery.
Recuvyra is a schedule two controlled drug which contains fentanyl, a pure μ-agonist synthetic opioid with a potency 100 times that of morphine1. Applied to the area between the shoulder blades by a needleless two-pronged adapter two to four hours prior to surgery, Elanco says Recuvyra provides at least four days of opioid analgesia, which is mainly due to the activation of the μ-opioid receptors inhibiting the perception of pain and the transmission of pain signals in the spinal cord and dorsal horn2.
Elanco says Recuvyra's unique formulation provides long-lasting analgesia by establishing a depot of fentanyl within the stratum corneum. The fentanyl in this depot undergoes passive diffusion down a concentration gradient, and is steadily released into the general circulation over a number of days.
Ed Whittle MA VetMB MRCVS, technical consultant at Elanco said: "Fentanyl is widely used in human health and its powerful analgesic properties are well known amongst veterinary surgeons1, 3, 4. Recuvyra is a ground-breaking veterinary product that will provide long-acting post-operative pain control in dogs while reducing the need for repeated, invasive administration of analgesics in the practice and improved client compliance and the potential for mutimodal analgesia once a dog returns home."
To ensure proper use of Recuvyra, Elanco has produced a mandatory online training programme for veterinary surgeons to complete before ordering the product. The brief online training module, which can be viewed at www.recuvyratraining.eu, features information on the presentation, correct preparation and administration of the product, and the safe handling of patients that have been treated with Recuvyra. Once veterinary surgeons are trained, it is their responsibility to train their staff on the in-practice use of Recuvyra and Elanco has produced a training presentation to help educate veterinary professionals about the product.
To support the launch of Recuvyra, Elanco has produced a dosing calculator, cage cards and client information sheet. For further information on Recuvyra, please contact your Elanco Companion Animal Health key account manager or email elancocah.uk@elanco.com.
The practice makes ecobricks by packing all sorts of plastic waste tightly into plastic bottles which can then be joined together using tyres, silicone, cob or cement and used for a wide range of purposes in gardens, play parks and for making all types of structures with.
The ecobrick initiative was launched by the Global Ecobrick Alliance, which describes itself as an Earth Enterprise focused on solving plastic pollution through the dissemination of the low-tech, educational, open source ecobrick technology. It also operates a website which lists a wide range of organisations throughout the world where newly-made ecobricks can be delivered to.
White Cross Vets operates 19 practices, with four in the local area in Gateacre, West Derby, St Helens and Widnes, and is now exploring how it can roll out the scheme across the group. Other green initiatives White Cross Vets is pioneering include rolling out energy efficient LED lighting across its practices and heavily promoting the Cycle to Work scheme.
Helen Morris, from White Cross Vets, said: "In our industry almost everything comes packed in unrecyclable plastics, from small syringe packets through to large delivery bags and the plastic on the backs of patient labels, which we print hundreds of every day.
"As a result, we decided to look at how we might be able to put it to good use, rather than simply putting it in the bin and came across ecobricks. By taking the time to fill the bottles with plastic, we can significantly reduce the waste we send to landfill, and cut the amount of plastic that ends up littering the planet and ultimately finds its way into the sea. We are now making them every week and the whole team gets involved, which is rewarding for everyone involved."
Bonqat 50 mg/ml oral solution for cats contains pregabalin, an analgesic, anti-epileptic which has now been licensed for the alleviation of acute anxiety and fear associated with transportation and veterinary visits in cats.
Tessie 0.3 mg/ml oral solution for dogs contains tasipimidine and is licensed for the short-term alleviation of situational anxiety and fear in dogs triggered by noise or owner departure.
Dômes Pharma points to research which shows that in the UK 1.4 million1 dogs show signs of distress when left alone, and 4.4 million dogs1 show fear of loud noises.
In addition, over 4 million cats2 are not having routine vet checkups each year, with 26%2 of these owners reporting that it is too stressful for their cat or themselves.
Jonathan Hill, UK country manager at Dômes Pharma sid: "Dômes Pharma is excited to be launching two new innovative products to help vets manage cases in this complex area.
"These products expand our portfolio and provide essential options for owners and their pets struggling with these situational related problems."
https://www.tvm-uk.com/the-behavioural-range
Fort Dodge Animal Health has announced that the European Medicines Agency (EMEA) has approved a new label claim for ProMeris Duo® for dogs. The new claim extends protection offered by ProMeris Duo to include "treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs".
Accoding to the company, dealing with demodectic mange on a dog has in the past been time-consuming for the pet owner and sometimes required vets to use a product off-label. Despite available measures, some dogs fail to respond to treatment and even require euthanasia due to the severity of the condition.
Rami Cobb, BVSc (Hons), MACVSc, Senior Vice President of Pharmaceutical Research and Development at Fort Dodge Animal Health said: "With the addition of the demodectic mange claim to the ProMeris Duo label, vets have the option of using the recognized efficacy of amitraz in a convenient spot-on formulation to treat and control this condition.
"When we conducted field studies for the label claim, the before and after pictures of the dogs treated with ProMeris Duo were remarkable. Visible improvements in the dog's condition were seen following the first treatment and in most cases, demodex mites could not be found after just a few months."
ProMeris Duo was evaluated for efficacy against demodectic mange mites in naturally infected dogs. Study results indicated dogs treated monthly with ProMeris Duo showed significant reduction in mite numbers and improvement in clinical signs after three months.
ProMeris Duo is now licensed for the following indications: For the treatment and prevention of infestations by fleas (Ctenocephalides canis and C. felis), as well as ticks (Ixodes ricinus, Ixodes hexagonus, Rhipicephalus sanguineus, Dermacentor reticulatus and Dermacentor variabilis), and treatment of demodicosis (caused by Demodex spp.) and lice (Trichodectes canis) in dogs. The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Publishing Editor Arlo Guthrie said: "I've lost count of the number of vets who remark that all veterinary recruitment adverts say that there's a 'happy working team' or a 'supportive environment', or 'all the latest toys' and it's only when they arrive at the practice that they discover that everyone's at each other like ferrets in a sack, and the practice's idea of 'all the latest toys' is a 1972 Goblin Teasmade."
VetSurgeon Jobs now includes the ability for advertisers to display in their advert links to the VetSurgeon profiles of other employees at the practice who are prepared to have an informal chat with candidates about what it's like working there.
Using the messaging system on VetSurgeon.org, the potential applicant and the employee can then arrange a time for a chat, without revealing the employee's email address, after which the candidate will hopefully feel far better placed to decide whether it's the job for them.
Arlo said: "Of course, no advertiser is going to display the name of an employee who is going to say bad things about the practice, but it still offers the chance for candidates to ask questions and make their own mind up before applying for an interview."
Aside from that, just the fact that a practice shows that it has the confidence in its employees to put them in touch with potential candidates says something very positive about those practices which use the feature.
To use the new feature, job advertisers need to enter the email address of another employee at the practice who is also a member of VetSurgeon.org and has agreed to talk to candidates, when they place their advertisement. When it goes live, the advert will then contain a direct link to the employee's profile, under the title: "Talk to other employees of this practice."
Sue qualified from Cambridge in 1984 and then spent time in mixed practice in Devon before taking her Certificate and then British and European Diplomas in Veterinary Dermatology.
Sue has been an RCVS and European Specialist for more than 20 years. She has recently been elected as a Fellow of the RCVS for meritorious contributions to clinical practice, is an elected member of the RCVS Council and is the Senior Vice President of the European Society of Veterinary Dermatology.
Sue is the Veterinary Director of two companies: Veterinary Dermatological Ltd, a manufacturer of a range of veterinary dermatology supplements, and Virtual Vet Derms, a veterinary telemedicine company. She has published seven text books as well as writing numerous peer reviewed articles and contributing chapters to both small animal and equine text books. She lectures extensively in Europe and America.
During her Presidency, Sue intends to consolidate everything she believes to be great about the Association. She said: "BSAVA has just completed a three-year strategic plan and my Presidency is going to be all about driving this forward. There are so many new initiatives in the pipeline I can’t wait to get started. I am looking forward to working with my dynamic teams of BSAVA officers and our amazing Woodrow House staff to show just how great BSAVA really is."
Professor Ian Ramsey becomes Vice President.
Trodax is used to treat the mature and late-immature stages of the liver fluke Fasciola hepatica in both cattle and sheep. It is also indicated for the treatment of Haemonchus contortus infections.
Findlay MacBean, Business Head for Ruminant, at Boehringer Ingelheim Animal Health said: “Manufacturing problems have led to Trodax being out of stock since late 2020 and it is with regret that we have to confirm that we are no longer able to manufacture the product.
"As one of the largest animal health businesses in the world we are committed to improving the lives and health of animals. We have a strong research and development focus, and a pipeline of potential products, including antiparasitics. We recognise that the discontinuation of Trodax may pose challenges for cattle and sheep producers where resistance to other flukicides has been confirmed.
“Our technical services team are on hand to support veterinary practice and animal health merchant customers as we make this change to our portfolio. Customers who have a technical enquiry should call 01344 746957 or email vetenquiries@boehringer-ingelheim.com.”
Boehringer says that its other wormer and flukicide brands are not affected and that Ivomec Super Injection, which contains ivermectin and clorsulon, provides an alternative treatment option for adult liver fluke in cattle and is also effective against gastrointestinal worm species, lungworm, and key external parasites.
Two analyses of the pet insurance market have been published this week, which together suggest that veterinary practices may be starting to price themselves out of the market.
Both reports are titled Pet Insurance 2014. In the first, published by Key Note Ltd, authors highlight a 35.4% increase in gross claims incurred on cat and dog insurance policies between 2009 and 2013, which is more than 5 times the increase in the volume of claims over the same period. It is the degree to which the value of claims has outstripped the volume which the report describes as 'undeniably the greatest factor affecting the UK market for pet insurance.
At the same time, there has been a relatively modest growth in the percentage of adults that own a cat or dog (around 1.5 percentage points). Consequently, premiums increased by 38.9% between 2009 and 2013 as insurers responded to the growing cost of claims.
Meanwhile, the other Pet Insurance 2014 report, this time from YouGov, has shown that the main factors limiting the uptake of pet insurance are poor value for money and the high cost of premiums. In 2012, 31% of owners without insurance said it was not good value for money, and that was the main reason for not taking out cover. By 2014, that figure had risen to 39% of the uninsured and 26% said they just cannot afford premiums.
According to the YouGov report, the words that uninsured pet owners most associate with pet insurance are 'expensive' (68%) and 'waste of money' (30%). Even 57% of those with insurance deem it expensive.
YouGov also highlighted that the number of uninsured pet owners who say they can afford to pay for veterinary treatment out of their own pockets (without setting money aside each month) has increased 4 percentage points from 15% in 2012 to 19% in 2014. YouGov hypothesises that this may be down to the improving economic situation in the UK, but it could equally be explained as just the way hard-pushed people self-justify their decision to discontinue insurance.
James McCoy, Research Director, YouGov Reports said: "Although social grade is important to being able to afford to take out pet insurance, our research suggests that those at different ends of the financial spectrum share the opinion that cover is not necessarily always a sound financial option.
"More affluent pet owners find insurance poor value because they can afford to pay for treatment up front; for less affluent pet owners, while pet insurance is perceived as offering good value for money, the cost of premiums is prohibitive, leading some to save money instead."
Dr Kettle faced a charge that he had grabbed the dog, a Shih Tzu named Bella, when she was in a kennel, and/or failed to take sufficient care to ensure that Bella did not fall from her kennel, hit Bella with his hand and/or muzzle, and carried Bella only by her collar and/or scruff.
At the outset, Dr Kettle admitted that he had committed the acts as alleged and that his conduct represented serious professional misconduct.
Having taken evidence from the College and the respondent into account, the Committee considered that Dr Kettle’s actions had not only placed Bella at risk of injury but had also caused her actual injury evidenced by her tongue turning blue for a few seconds, the fact that she soiled herself and her stillness in the treatment room.
However, it also concluded that the incident was a single episode in respect of a single animal that had occurred over a period of 30 seconds, so whilst his actions were serious, they were not aggravated by being sustained or repeated over a period of time.
In terms of mitigating factors, the Committee considered that the circumstances at the time of the incident were relevant.
It found Dr Kettle to be a credible witness and accepted that, during the time that the incident occurred, he had been going through a very difficult time personally with the loss of locum staff, the increased work pressure during the pandemic and unrelated adverse comments on social media.
The Committee considered that whilst these factors did not excuse his behaviour, they had affected how Dr Kettle had reacted towards Bella on the day.
The Committee also noted from clinical records that Dr Kettle had been Bella’s veterinary surgeon for over seven years, on nine occasions prior to the incident and on seven occasions subsequently.
There has been no such evidence of any other incidents happening within this time. Dr Kettle received highly positive testimonials attesting to his usual high standards of practice, both before and since the incident, and the Committee was satisfied that this incident could properly be characterised as isolated and out of character.
Kathryn Peaty, Chair of the Disciplinary Committee and speaking on its behalf, said: “It was clear that Dr Kettle was deeply remorseful and ashamed of his actions, immediately recognising the seriousness of what he had done.
"Indeed, it was apparent to the Committee from Dr Kettle’s evidence that this remorse and regret continue to weigh heavily on him.
“In all the circumstances, although the Committee did not consider that Dr Kettle’s misconduct was at the lower end of the spectrum of seriousness, given the absence of future risk to animals or the public, and the evidence of exemplary insight, the Committee concluded that a reprimand was the appropriate and proportionate sanction in this case.
“The Committee was satisfied that a reprimand would mark Dr Kettle’s misconduct and reassure the public that veterinary surgeons who act as Dr Kettle had done, would face regulatory consequences and sanction.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Veterinary surgeons are being advised against taking a heavy handed approach to hyperthyroidism by key opinion leaders, including Professor Danielle Gunn-Moore, a Specialist in Feline Medicine at the Royal (Dick) School of Veterinary Studies in Edinburgh.
Professor Gunn-Moore said: "Hyperthyroidism is not a condition that develops suddenly. It is a slowly progressive disease. The cat's body adapts to being hyperthyroid over a relatively long period of time. That is why it is best to return it to a euthyroid state in a controlled manner, rather than trying to crash the thyroxine concentration back down to normal as quickly as possible. Too fast a fall in thyroxine concentration can significantly exacerbate renal compromise and may cause serious harm.
"My recommendation is that you should start with a low dose of anti-thyroid medication and increase it if needed, after assessing the initial response to treatment. Any increase should be made in the smallest increments possible."
Dechra Veterinary Products - makers of Felimazole, the first medical treatment licensed in Europe for feline hyperthyroidism - is inviting vets to stand 700/701 at the BSAVA Congress to find out more about the latest thinking and new research which shows that treatment of hyperthyroid cats can result in iatrogenic hypothyroidism, that hyperthyroid cats are significantly more likely to develop azotaemia than euthyroid cats, and that hypothyroid cats that developed azotaemia have significantly shorter survival times.1
Further information on Felimazole is available by calling 01939 211 200 or visiting http://www.dechra.com/
References:1. Williams, T. et al (2010) JVIM 24: 1086-1092
The Kennel Club has launched Puppy Awareness Week to bring the horrors of puppy farming to the public consciousness and highlight the important steps that are needed when buying a puppy, such as choosing the right breed and finding a responsible breeder.
According to the organisation, 1 in 4 dog owners may have bought a puppy farmed dog. According to a survey it carried out this month, 44% of people don't even know what a puppy farm is, and 29% have bought a puppy from the Internet, a pet shop or a newspaper advert, all outlets which are often used for selling puppy farmed puppies. 60% admitted they did not see their puppy with its mother and more than half didn't see its breeding environment before they brought it home. 66% of owners were also never given the parents health certificates, and 8% were sold a puppy before it was 8 weeks old, which recent research has shown may lead to behavioural problems later in life.
The Kennel Club is concerned that the problem will get worse in the current economic climate, as 66% of people said they would buy a puppy at lower than the average price.
Caroline Kisko, Kennel Club Secretary, said: "Puppy farming is a cruel trade that treats dogs as commodities rather than living creatures. You wouldn't buy a commodity, such as a car, from a dodgy dealer offering no MOT or service documents, but people don't ask for the same assurances from a breeder when buying a dog.
"Our worry is that in the future even more people will be fooled by puppy farmers, who hide behind the internet, being drawn in by the knock down prices without being aware of the high cost that they will pay later. This will simply grow the abandoned dog population and result in even more suffering.
"It is absolutely vital that people go to a Kennel Club Assured Breeder or a rescue home and that they know what assurances and information they are entitled to when buying a puppy, or it will lead to hefty veterinary bills and heartache further down the line."
The Kennel Club is urging puppy buyers to go to a rescue home, or a Kennel Club Assured Breeder - the only scheme in the UK which sets standards for and monitors dog breeders. It has also called on the government to put in place standards, similar to those used by the Kennel Club Assured Breeder Scheme, for all breeders.
The Kennel Club has issued the following advice to puppy buyers:
The Kennel Club has also created a petition to help end puppy farming and hopes to reach 100,000 signatures so that it may be addressed in the House of Commons. Dog lovers are invited to add their support by visiting http://epetitions.direct.gov.uk/petitions/8557.
Puppy Awareness Week will culminate in Pup Aid, the boutique music festival, celebrity-judged fun dog show and family day out at Stanmer House in Brighton on 18th September, organised by TV vet Marc Abraham.
For further information, visit: www.thekennelclub.org.uk/paw.
A new infographic and educational webinar are now available to share on social media, to increase farmer awareness and provide best practice guidance.
The infographic and webinar explain how vaccination is considered best practice for control of the disease, giving better disease control whilst ensuring responsible use of antibiotics.
Independent sheep veterinary consultant Dr Fiona Lovatt, who leads the cross-industry Sheep Antibiotic Guardian Group, said: "Despite EAE being responsible for over 35% of all abortion diagnoses, only one million of the 3.5 million replacement ewes in the national flock each year are vaccinated against EAE. Any sheep farmer that either buys in ewes for replacements or has close neighbours that also lamb sheep, risks bringing enzootic abortion into their flock.
"Once the disease infects an unvaccinated flock, some ewes are ‘programmed’ to abort at their next lambing, leaving no choice but to put remedial measures in place – usually including both vaccination and antibiotic treatment.
"This means EAE is a disease that, once in a flock, carries high costs both financially and emotionally in terms of lamb losses and farmer stress. Hence it is important that flocks receive appropriate vaccination at least four weeks before ewes go to the ram and avoid the inappropriate use of antibiotics closer to lambing."
Fiona points out that a single dose of EAE vaccine costs about £2.40 and is an investment that effectively lasts the ewe for her lifetime in the flock, protecting against losses. In contrast, abortion or stillbirth – which accounts for around a quarter of all lamb losses each year – costs over £25 for every single lost lamb.
Fiona added: "Every injection of antibiotics also costs an additional £1. But is just a ‘sticking plaster’ with short-lasting effectiveness in terms of disease control but long-lasting damage in terms of mounting resistance."
Ceva says it will continue to work closely with veterinary practices to secure stock of Cevac Chlamydia vaccine to ensure farmers can purchase and use the vaccine at the right time. Ceva also provides subsidised blood sampling for diagnostic purposes.
For further information, call Ceva Animal Health on 01494 781510 or email cevauk@ceva.com.
Photo: Mike Benjamin
Headed by Esteban Gonzalez-Gasch, a European Specialist in Small Animal Surgery, the new department enables the practice to undertake a wide range of complex small animal procedures.
Injuries and conditions treated include fracture fixation, including complex and simple fractures; cruciate disease, including tibial osteotomies and extracapsular repair; arthroscopy; arthrodesis of chronically painful joints; elbow dysplasia; lameness investigation in adults and juveniles; treatment of growth deformities including distraction osteogenesis; osteoarthritis and musculo-skeletal neoplasia.
Esteban, who joined Southfields earlier this year from the leading Spanish veterinary hospital Ars Veterinaria, in Barcelona, said: "These new facilities really do put Southfields at the cutting edge of 21st century veterinary science and practice in the UK."
Southfields is also carrying out a full refurbishment of its existing facilities and recruiting a number of additional specialist veterinary surgeons, nurses and support staff.
Southfields’ operations manager Daniel Hogan said: "This is a very exciting period for us. We are growing in every possible area and working more closely with referring practices to continue to develop our bespoke and exceptional service for patients and clients.
"Our aim is aspiring and simple: to create the very best referral centre possible by bringing together the expertise of the very best of veterinary professionals supported by the very latest in technological innovation."
As well as orthopaedics, the practice accepts referrals in soft tissue surgery, internal medicine, oncology, neurology, feline medicine and cardiology. For more information, go to www.southfields.co.uk.
Medivet owns 245 veterinary practices in the UK and its rate of practice acquisition had tripled in the last 12 months.
CEO, Arnold Levy said: "The 25 strong Regional Directors Team is a key strategic line of management and support for all our existing practices, and they are central to the successful integration of our new practices into our hub and spoke model. Even though each of our Regional Directors is an experienced, qualified veterinary surgeon, it is vital that they have time, knowledge and understanding of the Medivet business and operation to confidently support their practices in line with our model, in the right way.
"With the support of the Leadership Team, we will be using these next few months to ensure this newly formed group have all the skills needed to do just that."
Arnold added: "We have taken this deliberate decision to ensure we can maintain the very highest standards of client and patient care. Where our management team and support structures are already in place we will continue with our new acquisitions program, and once our Regional Management operation is fully embedded, we will confidently continue to grow our business in a sustainable, people and patient-first way."
Policyholders will get unlimited access to Joii Pet Care’s video consultations with UK veterinary surgeons, which usually cost £24 per call.
Pet owners with Asda Money pet insurance will also be able to access Joii Pet Care’s symptom checker, which is designed to help pet owners pinpoint issues from their home.
Paul Hallett, co-founder of Vet-AI, said: “We’re delighted to announce this major partnership, which completely opens up access to professional vet care for thousands of pet parents who will benefit hugely from accessing regular, preventative veterinary care from the comfort of their homes.
“Many pet owners are now facing high vet bills and difficulties accessing in-practice veterinary care.
"Both Markerstudy Broking and Asda Money share our commitment to put animal welfare first, and collectively we’ll ensure more owners have easily accessible choice to receive the very best care for their pets.”